Baidu
map

Int J Clin Oncol:4天MEA治疗绒癌和高危GTN的疗效

2020-06-28 网络 网络

本研究旨在评估4天化疗与甲氨蝶呤、依托泊苷和放线菌素D(MEA)对诊断为绒癌和高危妊娠滋养细胞瘤(GTN)患者的疗效和毒性。

本研究旨在评估4天化疗与甲氨蝶呤、依托泊苷和放线菌素D(MEA)对诊断为绒癌和高危妊娠滋养细胞瘤(GTN)患者的疗效和毒性。

 

1999年1月至2015年12月期间,29名患者在被诊断为绒癌或高危GTN后接受了4天MEA治疗。对4天MEA的完全缓解和不良反应进行了回顾性评估。

 

结果,所有患者和接受4天MEA作为一线治疗的患者的完全缓解率分别为79.3%(23/29)和87.5%(21/24)。在6名对4天MEA产生耐药的患者中,有3名患者通过其他治疗出现完全缓解,另外3名患者因病死亡。主要不良反应为白细胞减少、贫血和恶心。在23例用4天MEA治愈的患者中,有14例患者因白细胞减少、肝毒性和口腔炎而改用依托泊苷和放线菌素D(EA)方案治疗。在20例需要激素治疗的患者中,15例患者治疗后月经周期正常。5例患者共受孕9次(7例足月活产,2例自然流产)。没有早产或出生体重过低的婴儿,也没有先天性畸形。

 

总之,该研究结果表明,4天MEA治疗绒癌和高危GTN的疗效和不良反应可能与EMA/CO处于同一水平。但如何确定将4天MEA治疗方案改为EA方案的标准,还需进一步研究。

 

原始出处:

 

Shizuka Sato, Eiko Yamamoto, et al., The Efficacy and Toxicity of 4-day Chemotherapy With Methotrexate, Etoposide and Actinomycin D in Patients With Choriocarcinoma and High-Risk Gestational Trophoblastic Neoplasia. Int J Clin Oncol. 2020 Jan;25(1):203-209. doi: 10.1007/s10147-019-01540-9.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=961851, encodeId=d251961851a5, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:28 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865860, encodeId=5f171865860cb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 06 20:20:22 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032557, encodeId=3272103255e66, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038061, encodeId=dd7e10380610e, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
    2021-04-30 MedSciZeng

    #J Clin Oncol#点击查看更多该期刊内容

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=961851, encodeId=d251961851a5, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:28 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865860, encodeId=5f171865860cb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 06 20:20:22 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032557, encodeId=3272103255e66, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038061, encodeId=dd7e10380610e, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
    2020-12-06 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=961851, encodeId=d251961851a5, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:28 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865860, encodeId=5f171865860cb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 06 20:20:22 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032557, encodeId=3272103255e66, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038061, encodeId=dd7e10380610e, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
    2020-06-28 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=961851, encodeId=d251961851a5, content=<a href='/topic/show?id=11cf104251a3' target=_blank style='color:#2F92EE;'>#J Clin Oncol#</a>点击查看更多该期刊内容, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104251, encryptionId=11cf104251a3, topicName=J Clin Oncol)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:17:28 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865860, encodeId=5f171865860cb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Dec 06 20:20:22 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032557, encodeId=3272103255e66, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038061, encodeId=dd7e10380610e, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Jun 28 19:20:22 CST 2020, time=2020-06-28, status=1, ipAttribution=)]
    2020-06-28 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

Pediatr Blood Cancer:中性粒细胞减少饮食与食品安全指南对小儿肿瘤患者感染率的有效性

中性粒细胞饮食(ND)是为了避免细菌进入宿主的胃肠道,减少感染。由于缺乏支持ND的证据,小儿肿瘤科医生对ND是否有用仍有争议。这项前瞻性随机对照试验评估了随机接受食品和药物管理局批准的食品安全指南(F

Support Care Cancer:多模态运动改善接受化疗的头颈部癌症患者的运动反应和身体成分

研究发现,很多化疗药物会对癌症患者产生多种副作用和并发症,尤其是在心血管疾病方面。本研究旨在探讨运动训练干预能否改善正在接受化疗的头颈部(H&N)癌症患者的身体成分和运动反应。

Cancer Immunol Immunother:混合多肽疫苗组合多烯紫杉醇和地塞米松治疗去势抵抗性前列腺癌研究

之前人们开发了一种包含20种混合多肽(KRM-20)的新的癌症疫苗来诱导细胞毒性T淋巴细胞,从而抵抗12种不同的肿瘤相关的抗原。最近,有研究人员在II期试验中调查了是否KRM-20组合多烯紫杉醇和地塞米松能够在去势抵抗性前列腺癌(CRPC)患者中增强抗肿瘤作用。研究是一个双盲、安慰剂对照和随机II期研究,研究人员在日本10个医疗中心招募了无化疗CRPC患者。符合要求的患者以1:1的比例随机分配在K

Lancet Oncol:系统化疗联合西妥昔单抗不能用于早期可切除结肠癌肝转移患者

研究发现,尽管西妥昔单抗-化疗对部分晚期不可切除肿瘤患者有效,但对于早期可切除结肠癌肝转移患者,系统化疗仍是手术后的首选治疗手段

Virol J:接受化疗的非移植性急性白血病患者合并感染人类疱疹病毒的情况

人类疱疹病毒(HHVs)在原发感染后仍有潜伏期,并可在免疫抑制和化疗后重新激活。对其在非移植性白血病患者中的发病率、潜在关系、危险因素和临床影响知之甚少。本研究调查了初诊急性白血病患者中HHVs-(1

J Clin Oncol:[ 18 F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对头颈癌的分期及在N0颈部的阴性预测价值和手术影响

本研究旨在确定正电子发射断层扫描(PET)/计算机断层扫描(CT)在颈部解剖的基础上对临床N0颈部的负预测值(NPV)。

Baidu
map
Baidu
map
Baidu
map